U.S. markets closed

Grifols, S.A. (G0F.F)

Frankfurt - Frankfurt Delayed Price. Currency in EUR
6.45+0.20 (+3.20%)
At close: 08:04AM CET

Grifols, S.A.

Avinguda de la Generalitat, 152
Parc empresarial Can Sant Joan Sant Cugat del VallEs
Barcelona 08174
34 93 571 02 21

IndustryDrug Manufacturers—General
Full Time Employees27,584

Key Executives

NameTitlePayExercisedYear Born
Mr. Steven Francis Mayer J.D.Exec. Chairman125kN/A1960
Mr. Raimon Grifols RouraCo-CEO & Exec. Director895kN/A1964
Mr. Víctor Grifols DeuCo-CEO & Exec. Director895kN/A1977
Mr. Alfredo Arroyo GuerraCFO & VPN/AN/A1958
Mrs. Eva Bastida TubauCorp. VP and Director of Scientific & Medical AffairsN/AN/AN/A
Ms. Nuria Pascual LapeñaVP of Corp. Treasury, Risk Management Investor Relation & Sustainability OfficerN/AN/A1964
Mr. David Ian BellGen. Counsel & Chief Corp. Devel. OfficerN/AN/A1954
Mr. Mateo Florencio Borrás HumbertCorp. VP & Chief HR OfficerN/AN/A1956
Ms. Maria Teresa-Rioné LlanoChief Communications OfficerN/AN/A1965
Ms. Montserrat Gaja LlamasChief HR OfficerN/AN/A1965
Amounts are as of December 31, 2021 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in EUR.


Grifols, S.A. engages in the procurement, manufacture, preparation, and sale of therapeutic products, primarily hemoderivatives. The company operates through Bioscience, Hospital, Diagnostic, Bio Supplies, and Others divisions. The Bioscience division researches, develops, produces, and markets plasma-derived medicines and other innovative solutions to treat patients with chronic, rare, prevalent, and life-threatening diseases. It offers immunoglobulins, alpha-1 antitrypsin, albumin, clotting factors, and hyperimmune globulins. The Hospital division offers non-biological pharmaceutical products and medical supplies clinical nutrition, intravenous therapy, and medical devices. The Diagnostic division researches, develops, produces, and commercializes diagnostic products that span the healthcare continuum–from prevention, screening, diagnosis, and prognosis to disease and treatment monitoring–to serve professionals. The Bio Supplies division provides biological materials for life-science research, clinical trials, and for manufacturing pharmaceutical and diagnostic products. Its products and services are used by healthcare providers to diagnose and treat patients with hemophilia, immune deficiencies, infectious diseases, and other medical conditions. The company serves public and private customers; and wholesalers, distributors, group purchasing organizations, blood banks, hospitals and care institutions, and national health systems. Grifols, S.A. has a technology collaboration agreement with Mondragon. The company was founded in 1940 and is headquartered in Barcelona, Spain.

Corporate Governance

Grifols, S.A.’s ISS Governance QualityScore as of February 1, 2023 is 4. The pillar scores are Audit: 2; Board: 6; Shareholder Rights: 8; Compensation: 4.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.